v3.26.1
STOCK-BASED COMPENSATION
12 Months Ended
Dec. 31, 2025
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION

NOTE 5: STOCK-BASED COMPENSATION

 

The Company has an equity incentive plan for grants to employees, officers, consultants, directors, and other service providers that was approved in 2021 (the “2021 Plan”). The 2021 Plan provides for the grant of non-qualified stock options, incentive stock options, restricted stock awards, restricted stock units, unrestricted stock awards, stock appreciation rights and other forms of stock-based compensation. The 2021 Plan permits the Company’s board to change the type, terms, and conditions of awards as circumstances may change. This flexibility to adjust the type of compensation to be granted is particularly important given current economic and world events.

 

A summary of the stock option activity during the period ended December 31, 2025, is presented in the table below:

 

       Weighted average     
   Number of
options
   Exercise
price
   Remaining
contractual life
(in years)
   Intrinsic value 
Outstanding as of January 1, 2025   103,114   $225.68    7.6   $- 
Granted   28,301   $2.80    -   $- 
Forfeited and cancelled   (7,508)  $-    -   $- 
Outstanding as of December 31, 2025   123,907   $104.70    7.3   $24,000 
Exercisable as of December 31, 2025   80,373   $153.26    6.2   $- 
Vested and expected to vest as of December 31, 2025   123,907   $104.70    7.3   $24,000 

 

In addition, on December 22, 2025, in connection with the Investment Transaction with David E. Lazar, see Note 6(e), the Company entered into employment modification agreements (the “Modification Agreements”) with its executive officers. Pursuant to the Modification Agreements, the executive officers agreed to reduce the notice period for termination for any reason to 10 days and waive the severance benefits under their original employment agreements in exchange for a combination of an equity settlement payment in lieu of cash payable in 350,000 shares of common stock, based on $2.03 per share, and a cash payment of approximately $3.50 million.

 

The following table summarizes the total stock-based compensation expense included in the consolidated statements of operations for the periods presented:

 

   2025   2024 
   For the year ended December 31, 
   2025   2024 
Research and development  $287,675   $624,480 
General and administrative   1,070,407    1,681,369 
Total stock-based compensation expense  $1,358,082   $2,305,849 

 

As of December 31, 2025, total compensation cost not yet recognized related to unvested stock options was approximately $0.26 million, which is expected to be recognized over a weighted-average period of approximately 1.2 years.

 

 

The Company estimates the fair value of stock options on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires estimates of highly subjective assumptions, which affect the fair value of each stock option. The weighted average inputs used to measure the value of the options granted during the years ended December 31, 2025 and 2024 are presented in the table below. The weighted average fair value of stock options issued during the years ended December 31, 2025 and 2024 was $6.72 and $36.68 per share, respectively.

 

   2025   2024 
Exercise price  $7.69   $43.12 
Expected term (in years)   5.6    5.8 
Volatility   124.9%   114.78%
Risk free rate   4.0%   4.0%
Dividend yield   0%   0.0%

 

The following table presents the exercise price of outstanding stock options as of December 31, 2025:

 

Exercise price  Options
outstanding
 
     
$0.01 - $80.00   75,288 
$0.01 - $80.00   75,288 
$80.01 or higher   48,619 
Total   123,907